Blauvelt A, Ladizinski B, Prajapati VH, Laquer V, et al. Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up). J Am Acad Dermatol 2023 May 23:S0190-9622(23)00966.
PMID: 37230366